Among the five different subtypes, two prominent challenges have emerged in the management of breast cancer: resistance to endocrine therapy in estrogen receptor ER(+) tumors [2] and heterogeneous response to anti-HER2 therapy in HER2(+) tumors [3]. The gene discussed is ERBB2; the disease is breast carcinoma.